Kenneth Galbraith

Kenneth Galbraith

CEO, President & ChairatZymeworks· In proxies 2022–2025

Pay in FY2025+26% from the year before · Zymeworks stock +79.8% the same year

Kenneth Galbraith was paid $6.6M in FY2025 (Dec), up 26%. Zymeworks stock rose 79.8% that year.

Pay$100 in the stock at the end of FY21 → $122
Pay is from the Summary Compensation Table of each Zymeworks proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. ZymeworksPublic company · 4 yr
    • CEO, President & Chair2022 – Present · 4 yrStock in role +83%
  2. Profound Medical Corp.Public company · 6 yr
    • Director2017 – 2023 · 6 yrNo stock prices for these years
  3. MacroGenics, Inc.Public company · 14 yr
    • Director2008 – 2022 · 14 yrNo stock prices for these years
  4. Celator Pharmaceuticals, Inc.Public company · 5 yr
    • Director2008 – 2013 · 5 yrNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?